Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.52 |
| ▸ | GRM5 | P41594 | 11/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409265 | 0.91 | GRM1 (0.52) | GRM1GRM5WNT3AGPR119PDK4 | |
| SCHEMBL18409266 | 0.89 | GRM1 (0.42) | GRM1GRM5WNT3AGPR119PDK4 | |
| SCHEMBL17614636 | 0.86 | GRM1 (0.52) | GRM1GRM5WNT3AGPR119PDK4 | |
| SCHEMBL25480363 | 0.85 | GRM1 (0.51) | GRM1GRM5WNT3AGPR119PDK4 | |
| SCHEMBL23730448 | 0.85 | GRM1 (0.56) | GRM1GRM5WNT3AGPR119PDK4 | |
| SCHEMBL19203191 | 0.83 | GRM1 (0.53) | GRM1GRM5WNT3AGPR119PDK4 | |
| SCHEMBL15024195 | 0.81 | GRM1 (0.60) | GRM1GRM5WNT3APDK4NAMPT | |
| SCHEMBL23703974 | 0.80 | GRM1 (0.53) | GRM1GRM5WNT3AGPR119PDK4 | |
| SCHEMBL15001502 | 0.80 | GRM1 (0.53) | GRM1GRM5WNT3APDK4CYP11B2 | |
| SCHEMBL23730450 | 0.79 | GRM1 (0.52) | GRM1GRM5WNT3AGPR119PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |